Chapters

Transcript

Video

Even though biopharmaceuticals and biosimilars are made in different manufacturing contexts, do we have data to confirm that such differences are clinically insignificant in the case of biosimilars for infliximab used in RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA